about
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzkaPolymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung CancerThe application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients.Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancerPolymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.Immunological system status and the appearance of respiratory system disturbances in thymectomized patients.The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancerImpact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary diseaseMechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system.Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients.The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings.The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma.Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report.Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease.New Dancing Couple: PD-L1 and MicroRNA.Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.'TB or not TB?' Problems of differential diagnosis of cutaneous mycobacteriosis and tuberculosis--A Case Study and interdisciplinary discussion.Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer.Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes.Letter to the editor concerning first-line therapy with afatinib - an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations.EGFR gene mutations in patients with adenosquamous lung carcinoma.Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique.Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection.Prognostic value of synaptophysin and chromogranin a expression in patients receiving palliative chemotherapy for advanced non-small-cell lung cancer.The yield of endobronchial biopsy in pulmonary sarcoidosis: connection between spirometric impairment and lymphocyte subpopulations in bronchoalveolar lavage fluid.Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer.The presence and clinical implications of α-2,6-galactose-linked sialic acids in non-small-cell lung cancer brain metastases--preliminary study.
P50
Q33683680-99F0DE32-2ACB-457E-B09D-A94784389DFDQ33751194-88B96DD7-462B-458E-BC44-E2C7A7D33CFBQ33792750-58DDC654-C795-42A7-8A8A-D92248F4DB06Q33844457-C8DF5521-E76C-47F5-9715-6C404BD3DBBCQ34253217-F71EDD10-B424-4B32-96AE-C7BB7F4E2D9BQ34271013-70499FBE-61A3-488A-9E75-E0150833E5D2Q34491507-2934D45C-8449-4104-9281-1FABDF1B7666Q34809526-189F6974-E934-4391-BD33-B860F45E1C8DQ35602536-C19B9732-C52A-4F8B-9227-55A726B94CBBQ35700740-84F380B3-1B0A-441D-8360-C0A93887DDE2Q35967971-C74C34AA-A426-412C-AC21-3B9B15F23D18Q36378565-DC306171-C2AB-466E-9814-C2FB6A3561E4Q36834504-C5ECE5F9-66F5-456B-85AF-BCCEAFDE479AQ36845267-874E5F7C-8F42-4801-80A9-CCF1D7CE3F30Q36942619-0E2D9598-BE18-41BF-BB64-4DA7EBF96929Q37198266-A04DA29D-F55D-4DEF-B850-C72489876D81Q37229404-BBF30338-5C02-4223-B104-F3DBD91E18BCQ37245874-0F526166-64C9-48AB-AB33-9850A5651B05Q37397746-B9E78E08-B3BB-4282-BA34-0B1BDBC54BC4Q37412625-1F978173-9D85-447D-B081-2C8CD1C93320Q37470875-3F80F9D7-DC8F-494C-884F-74A263F56B5AQ37677042-D3A0A2CB-1E76-449C-BC11-FB9F4C19F620Q37692104-E212C7B6-1CDA-4CC2-96BC-C33A88AD9C23Q39017830-436D10F0-FFF1-4F14-B23F-378B513A6C16Q39413337-B9344AAD-7FFB-4E19-88AC-8341F78CD95BQ40429723-172DB80E-4E70-49E4-B7AF-9D59E93F6372Q40743859-8658148E-9570-49A9-A392-192F3F4081E4Q41030204-4165BCF9-1DD5-4023-B322-C92BC2760908Q41608748-2ADD6EF9-A7D0-4837-8A03-BB61D3E8D974Q42061324-3D7385B6-D381-4C9B-AA6A-FA423752651CQ43190679-BDEF4952-4762-490F-994F-F682E17A6569Q44690866-9819CC4E-44F3-4D8B-AB55-C9B4FEC0107AQ47095636-FE551192-83D8-40FB-8C0D-97337B461662Q47143835-A57F3FC5-DF03-493D-A66A-13A4268E020CQ47686349-0FA5DFBC-7E5D-48CD-8E91-2B57212E8E2FQ47757715-99F25AB6-7A9B-4F78-85EB-747740AB1F80Q47947285-F0A453F8-6A7F-4AE0-8AA8-BEAB507BAE3BQ48020575-F0C31CAD-3C08-482E-A576-A0533EC7DF44Q48419474-2F4C0257-CF9B-4755-8C0A-B9DE00BE3837Q48668746-1F16750F-685B-4DEA-86B0-FC08872D4D98
P50
description
Polish researcher and oncologist
@en
polski lekarz, onkolog
@pl
name
Paweł Krawczyk
@ast
Paweł Krawczyk
@en
Paweł Krawczyk
@es
Paweł Krawczyk
@nl
Paweł Krawczyk
@pl
type
label
Paweł Krawczyk
@ast
Paweł Krawczyk
@en
Paweł Krawczyk
@es
Paweł Krawczyk
@nl
Paweł Krawczyk
@pl
altLabel
Pawel Krawczyk
@en
prefLabel
Paweł Krawczyk
@ast
Paweł Krawczyk
@en
Paweł Krawczyk
@es
Paweł Krawczyk
@nl
Paweł Krawczyk
@pl
P1153
55966840100
6701497469
P21
P31
P496
0000-0001-8400-4452